Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 18/20 | 0.44 |
| ▸ | LOX | P28300 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28746203 | 0.85 | HCAR2 (0.48) | HCAR2LOXL2LOXKDM4EALDH1A1 | |
| SCHEMBL2643242 | 0.84 | LOXL2 (0.43) | LOXL2LOX | |
| SCHEMBL5492565 | 0.82 | LOXL2 (0.41) | HCAR2LOXL2LOXKDM4EALDH1A1 | |
| SCHEMBL3843156 | 0.82 | HCAR2 (0.53) | HCAR2KDM4EALDH1A1GAA | |
| SCHEMBL7408783 | 0.80 | HCAR2 (0.52) | HCAR2KDM4EALDH1A1GAA | |
| SCHEMBL1912545 | 0.80 | HCAR2 (0.57) | HCAR2LOXL2KDM4EALDH1A1GAA | |
| SCHEMBL9642872 | 0.80 | HCAR2 (0.52) | HCAR2KDM4EALDH1A1GAA | |
| SCHEMBL7841478 | 0.80 | HCAR2 (0.52) | HCAR2LOXL2KDM4EALDH1A1GAA | |
| SCHEMBL9643962 | 0.80 | HCAR2 (0.52) | HCAR2KDM4EALDH1A1GAA | |
| SCHEMBL18792376 | 0.77 | HCAR2 (0.48) | HCAR2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169759-B1 | Tetrapeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | claimed |
| EP-1192177-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000077030-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-5849693-A | Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5773411-A | CARDIOVASCULAR DISORDERS AND BRAIN DISORDERS AND COAGULANTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0672059-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994011398-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |